Deucravacitinib in Plaque Psoriasis: 4-year Safety and Efficacy Results from the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials. J of Skin. 2024;8(6):s423. doi:10.25251/skin.8.supp.423